Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment-An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse.
P Joy HoAndrew SpencerPeter MolleeChristian E BryantAnoop K EnjetiNoemi HorvathBelinda E ButcherJudith TrotmanSimon GibbsDouglas E JoshuaPublished in: Clinical lymphoma, myeloma & leukemia (2024)
reduction in involved SFLC at Cycle 2 Day 1 is an appropriate target for reducing the risk of dialysis in myeloma patients with RI; below this threshold patients may benefit from a change in therapy. While Cfz-dexamethasone achieved favorable renal and disease outcomes, toxicity can be significant in this vulnerable cohort.
Keyphrases
- end stage renal disease
- newly diagnosed
- multiple myeloma
- chronic kidney disease
- peritoneal dialysis
- low dose
- high dose
- ejection fraction
- clinical trial
- oxidative stress
- prognostic factors
- type diabetes
- randomized controlled trial
- mesenchymal stem cells
- skeletal muscle
- free survival
- smoking cessation
- double blind
- replacement therapy
- bone marrow